For IVD manufacturers, the emergence of a novel virus is challenging as the detection of such viruses require quickly developed, novel diagnostic solutions.
However, existing regulations in place to protect the public’s health and safety can impede the rapid development and deployment of novel IVD tests.
As a result, regulatory agencies across the world are adapting guidelines while COVID-19 remains an active pandemic. Continuous coordination with industry stakeholders will enable the quick and effective development of new and effective diagnostics. Some government bodies are advising developers to initiate communications with government agencies early on, allowing regulatory experts to help review data on a rolling basis for fast track development and market access.
Also, establishing guidance and adherence, will create transparency, which is required to mitigate potential adverse events from poorly designed tests and facilitate more informed decisions by potential buyers and users. Ultimately, ensuring proper validation is integral to the health and safety of patients and the clinical utility of the diagnostic.
Due to the revisions and modifications regulatory agencies are making to current guidelines and policies to enable the much needed diagnostic response, more than 40 COVID-19 diagnostics globally have launched over the past couple of months. In this blog, we provide an overview of regulatory changes occurring in diagnostics amid COVID-19.
Shifting regulations within the U.S.
In an effort to expedite the availability of diagnostic tests in the United States, the U.S. Department of Health and Human Services declared authorisation of emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the coronavirus in early February. Following this announcement, the FDA issued a guidance describing policies for laboratories and commercial manufacturers, to expedite the availability of IVDs. This guidance included revised testing recommendations to ensure analytical and clinical validity expeditiously, in addition to providing templates required for emergency use authorisation (EUA) submissions.
Further, the FDA’s guidance allows distribution of validated tests prior to EUA submission, but the information for use (protocol) is not released to the public until the EUA is granted. Specifically, the FDA notes that 15 business days is a reasonable amount of time for manufacturers to prepare and submit an EUA. However, this policy does not apply to at-home tests.
Adapting current regulations in Europe
The World Health Organization (WHO) classified the COVID-19 outbreak as a public health emergency of international concern in January. WHO Emergency Use Listing (EUL) procedure is a way to evaluate IVDs in development that can address the COVID-19 outbreak. The WHO has continuously stressed the need for IVDs for screening and diagnosis, and aims to expedite the availability of IVDs. Additionally, the organisation published validation requirements for IVDs based on the detection of specific nucleic acid.
In early April, the European Commission issued a guidance, which includes in vitro diagnostic medical devices, specific to the pandemic, summarising harmonised standards, derogation procedures, and the recent proposal to postpone the application date of the European Union Medical Devices Regulation by one year. Under the current IVD Directive, the majority of IVD devices are self-certified by manufactures for conformance. Therefore, if an assay meets the specific classification requirements outlined in the IVD Directive, it does not require an independent assessment of conformity by a notified body to be CE marked.
Evolving diagnostic regulations in APAC region
At the onset of the outbreak, South Korea’s Centers for Disease Control and Prevention quickly coordinated with manufacturers to develop and ensure regulatory approval of the first diagnostic. Upon evaluation by government and medical academic experts, this diagnostic was granted emergency use authorisation by the Ministry of Food and Drug Safety and applied swiftly across the country.
Many countries within the Asia-Pacific region — including Singapore and Australia — soon followed suit, relaxing regulatory guidelines to address the overwhelming diagnostic testing needs caused by COVID-19. In addition, in February, China’s Center for Medical Device Evaluation (CMDE) announced adjustments to its medical device application acceptance and consultation services to expedite review and approval. The CMDE published two new guidelines on nucleic acid detection reagents and antigen/antibody detection reagents designed for IVDs in the detection of the coronavirus.
Partnering with diagnostics experts
Manufacturers operating with effective quality measures and the ability to create validated assays will be better positioned for efficient and positive assessment by regulatory agencies. At ICON, our diagnostics team can assist in navigating validation and the evolving regulatory landscape. Contact us to speak with our experts today.
COVID-19 clinical operations
Keeping your clinical trial on track in an evolving environment.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
- EU Regulations
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
-
test insights page
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
test insights page
-
Transforming Trials
-
Digitising COAs
-
Linguistic validation of Clinical Outcomes Assessments
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Supporting a top 10 pharma to transition to Veeva Vault platform
-
Transforming the R&D Model to Sustain Growth
-
Digitising COAs
-
Value Based Healthcare
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
US payers and PROs
-
Blog
-
Videos
-
Webinar Channel